BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
739 results:

  • 1. EMP1 correlated with cancer progression and immune characteristics in pan-cancer and ovarian cancer.
    Zhang J; Yang J; Li X; Mao L; Zhang Y; Liu Y; Bao Y
    Mol Genet Genomics; 2024 May; 299(1):51. PubMed ID: 38743077
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Artificial neural network identified a 20-gene panel in predicting immunotherapy response and survival benefits after anti-PD1/pd-l1 treatment in glioblastoma patients.
    Wang Y; Wang Z; Guo X; Cao Y; Xing H; Wang Y; Xing B; Wang Y; Yao Y; Ma W
    Cancer Med; 2024 May; 13(9):e7218. PubMed ID: 38733169
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy.
    Kim HM; Kim KJ; Lee K; Yoon MJ; Choih J; Hong TJ; Cho EJ; Jung HJ; Kim J; Park JS; Na HY; Heo YS; Park CG; Park H; Han S; Bae D
    BMC Immunol; 2024 May; 25(1):29. PubMed ID: 38730320
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Efficacy and safety of PD-1/pd-l1 inhibitors in elderly patients with advanced non-small cell lung cancer.
    Li L; Xu C; Wang W; Zhang Q
    Clin Respir J; 2024 May; 18(5):e13763. PubMed ID: 38717297
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
    Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
    J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma.
    Giordano C; Marrone L; Romano S; Della Pepa GM; Donzelli CM; Tufano M; Capasso M; Lasorsa VA; Quintavalle C; Guerri G; Martucci M; Auricchio A; Gessi M; Sala E; Olivi A; Romano MF; Gaudino S
    Cancer Res Commun; 2024 May; 4(5):1296-1306. PubMed ID: 38651817
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis.
    Shi H; Sun X; Wu Y; Cui Q; Sun S; Ji N; Liu Y
    J Clin Neurosci; 2024 Jun; 124():36-46. PubMed ID: 38642434
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Analysis of the sodium pump subunit ATP1A3 in glioma patients: Potential value in prognostic prediction and immunotherapy.
    Lan YL; Zou S; Qin B; Zhu X
    Int Immunopharmacol; 2024 May; 133():112045. PubMed ID: 38615384
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. PD-1/pd-l1 axis is involved in the interaction between microglial polarization and glioma.
    Wang XP; Guo W; Chen YF; Hong C; Ji J; Zhang XY; Dong YF; Sun XL
    Int Immunopharmacol; 2024 May; 133():112074. PubMed ID: 38615383
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung cancer Treated with PD-1/pd-l1 Inhibitors: A Single Institutional Cohort Study.
    Yuan Q; Xu C; Wang W; Zhang Q
    Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. pd-l1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence.
    Huang L; Chen S; Liu H; Meng L; Liu C; Wu X; Wang Y; Luo S; Tu H; Wang C; Zhang M; Gong X
    Cancer Med; 2024 Apr; 13(7):e7125. PubMed ID: 38613182
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review.
    Wang T; Zhang L; Cheng Y
    Chin Clin Oncol; 2024 Apr; 13(2):26. PubMed ID: 38600808
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Expression of immune checkpoints pd-l1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
    Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
    Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer.
    Divan HA; Bittoni MA; Krishna A; Carbone DP
    BMC Cancer; 2024 Apr; 24(1):424. PubMed ID: 38580900
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Relevance of Thymic Stromal Lymphopoietin on the Pathogenesis of Glioblastoma: Role of the Neutrophil.
    Infante Cruz A; Coronel JV; Saibene Vélez P; Remes Lenicov F; Iturrizaga J; Abelleyro M; Rosato M; Shiromizu CM; Candolfi M; Vermeulen M; Jancic C; Yasuda E; Berner S; Villaverde MS; Salamone GV
    Cell Mol Neurobiol; 2024 Apr; 44(1):31. PubMed ID: 38557942
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer.
    Zhou Y; Li H; Zhang Y; Zhao E; Huang C; Pan X; Shu F; Liu Z; Tang N; Li F; Liao W
    Cancer Lett; 2024 May; 589():216836. PubMed ID: 38556105
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients.
    Luo S; Liu Z; Chang H; Cheng X; Qian R; Gao Y; Hou C
    Aging (Albany NY); 2024 Mar; 16(7):6188-6211. PubMed ID: 38552216
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Associations of PD-1 and pd-l1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
    Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
    Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Outcomes of Patients with Non-Small Cell Lung cancer and brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.
    Nannini S; Guisier F; Curcio H; Ricordel C; Demontrond P; Abdallahoui S; Baloglu S; Greillier L; Chouaid C; Schott R
    Curr Oncol; 2024 Mar; 31(3):1656-1666. PubMed ID: 38534959
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
    Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 37.